Professor of Medicine, Dana-Farber Cancer Institute
Hematology
Dr. Donald W. Kufe, MD
|
|
Give Review
Donald Kufe works in the field of Hematology. He studied medicine at University of Rochester School of Medicine and Dentistry. He received awards:"Elected Member". Donald Kufe is a published physician. He has 44 publications published. The most current publication "MUC1-C drives MYC in multiple myeloma."
Publications
- MUC1-C drives MYC in multiple myeloma.
- MUC1-C Induces the LIN28BâLET-7âHMGA2 Axis to Regulate Self-Renewal in NSCLC.
- MUC1-C activates the TAK1 inflammatory pathway in colon cancer.
- Targeting the Oncogenic MUC1-C Protein Inhibits Mutant EGFR-Mediated Signaling and Survival in Non-Small Cell Lung Cancer Cells.
- MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells.
- Targeting the MUC1-C oncoprotein is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated multiple myeloma cell death.
- MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.
- MUC1-C Oncoprotein Activates ERK->C/EBPβ Signaling and Induction of Aldehyde Dehydrogenase 1A1 in Breast Cancer Cells.
- MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells.
- Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.
- Oncogenic MUC1-C Promotes Tamoxifen Resistance in Human Breast Cancer.
- Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients.
- MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition.
- Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein.
- MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches.
- Lenalidomide enhances anti-myeloma cellular immunity.
- MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells.
- Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells.
- Cooperative Interaction between the MUC1-C Oncoprotein and the Rab31 GTPase in Estrogen Receptor-Positive Breast Cancer Cells.
- A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas.
- The MUC1-C Oncoprotein Binds to the BH3 Domain of the Pro-apoptotic BAX Protein and Blocks BAX Function.
- Dendritic/tumor fusion cells as cancer vaccines.
- MUC1-C Oncoprotein Induces TCF7L2 Transcription Factor Activation and Promotes Cyclin D1 Expression in Human Breast Cancer Cells.
- CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.
- CBP501-calmodulin binding contributes to sensitizing tumor cells to CDDP and BLM.
- Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors.
- Ad.Egr-TNF and local ionizing radiation suppress metastases by interferon-beta-dependent activation of antigen-specific CD8+ T cells.
- Functional targeting of the MUC1 oncogene in human cancers.
- MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment.
- MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer.
- Targeting the human MUC1 oncoprotein: a tale of two proteins.
- Inhibition of nuclear factor-kappaB activity by temozolomide involves O6-methylguanine induced inhibition of p65 DNA binding.
- Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint.
- Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12.
- Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma.
- A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities.
- Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity.
- Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients w...
- Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.
- Transcriptional control of viral gene therapy by cisplatin.
- Manganese superoxide dismutase (SOD2) inhibits radiation-induced apoptosis by stabilization of the mitochondrial membrane.
- Tumor production of angiostatin is enhanced after exposure to TNF-alpha.
- Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance.
Schools
University Of Rochester
Beth Israel Hospital Boston
George Washington University Hospdc
Harvard Med School
Sidney Farber Cancer Institute
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- Elected Member
Education
-
George Washington University -
Beth Israel Deaconess Medical Center -
University of Rochester School of Medicine and Dentistry
Hospital
-
Dana-Farber Cancer Institute
Helpful Reviews
Similar Doctors
|
|
Dr. Robert F. Donnell, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. David A. Roth, MD |
|
|
Dr. Panagiotis Konstantinopoulos, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Marc B. Garnick, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Andrew M. Evens, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert E. Martell, MD
This Doctor is OpenDoctor Recommended.
|